Порівняння методів
Переглядайте обрані методи поруч; рядки з відмінностями підсвічено.
| Цільово-опосередкований розподіл препарату× | Фізіологічно-базована фармакокінетика× | |
|---|---|---|
| Галузь | Фармакологія | Фармакологія |
| Родина | Process / pipeline | Process / pipeline |
| Рік появи≠ | 2001 | 1997 |
| Автор методу≠ | Donald Mager and William Jusko | Ivan Nestorov |
| Тип≠ | nonlinear PK modeling | predictive modeling |
| Основоположне джерело≠ | Mager, D. E., & Jusko, W. J. (2001). General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics, 28(6), 507-532. DOI ↗ | Nestorov, I. (1997). Sensitivity analysis of pharmacokinetic and pharmacodynamic systems. Journal of Pharmacokinetics and Biopharmaceutics, 25(4), 529-543. link ↗ |
| Інші назви | TMDD, target-driven clearance | PBPK, PBPK modeling |
| Пов'язані | 3 | 3 |
| Підсумок≠ | Target-mediated drug disposition (TMDD) is a mechanistic framework describing nonlinear pharmacokinetics arising from drug binding to a target receptor or protein. Developed by Mager and Jusko in 2001, TMDD explains saturable clearance, dose-dependent half-lives, and time-dependent changes in plasma concentrations observed with protein therapeutics and some small-molecule drugs. | PBPK is a mechanistic modeling framework that uses physiological parameters, tissue properties, and drug-specific attributes to predict drug concentration time profiles in the body. Developed rigorously in the 1990s by researchers including Nestorov, PBPK integrates anatomy, biochemistry, and kinetics to enable rational drug development, bridging in vitro data to clinical outcomes. |
| ScholarGateНабір даних ↗ |
|
|